CAC
KNSA icon

Cowen and Company’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cowen and Company’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$139K – 656
2021
Q2 		$139K Buy
+10,000
New +$152K 0.01% 310

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Cowen and Company's KNSA Position: Q3 2021 in Review

Cowen and Company sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2021, closing a stake of 10,000 shares — an estimated $139K sold.

Cowen and Company first reported a position in KNSA in Q2 2021 and held it in 1 quarter. The position peaked at $139K in Q2 2021. 101 funds tracked by Wall St. Rank hold KNSA as of Q3 2021.

  • Cowen and Company reported no remaining Kiniksa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cowen and Company sold 10,000 Kiniksa Pharmaceuticals shares in Q3 2021, an estimated $139K.
  • Cowen and Company first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Cowen and Company's Kiniksa Pharmaceuticals position peaked at $139K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.